# Targeting Metastatic Breast Cancers by Alkaline Glucosodiene Molecules Via a Metabolic Pathway Phase I Clinical Trial

> **NCT05957939** · PHASE1 · UNKNOWN · sponsor: **Ministry of Health, Saudi Arabia** · enrollment: 2 (estimated)

## Conditions studied

- TNBC - Triple-Negative Breast Cancer

## Interventions

- **DRUG:** Alkaline Glucosodiene Molecules

## Key facts

- **NCT ID:** NCT05957939
- **Lead sponsor:** Ministry of Health, Saudi Arabia
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 2 (ESTIMATED)
- **Last updated:** 2023-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05957939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05957939, "Targeting Metastatic Breast Cancers by Alkaline Glucosodiene Molecules Via a Metabolic Pathway Phase I Clinical Trial". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT05957939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*